2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis

@article{mukhtyar20262025,
  title = {{2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis}},
  author = {Chetan B. Mukhtyar and Elena Nikiphorou and Alice Bartoletti and Mrinalini Dey and Georgina Ducker and Durga Prasanna Misra and Sara Monti and Paul Studenic and Alvise Berti and Daniël Blockmans and Elisabeth Brouwer and Frank Buttgereit and Kathleen Cannings and Maria Cinta Cid and Richard P. Conway and Lisa Christ and Christian Dejaco and Kresten Krarup Keller and Lisa Christ and Peter A. Merkel and Aladdin J Mohammad and Susan P. Mollan and Berit Dalsgaard Nielsen and Cristina Ponte and David Saadoun and Wolfgang Schmidt and Kenneth J. Warrington and Bernhard Hellmich},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  month = jul,
  doi = {10.1016/j.ard.2026.06.009},
  url = {https://doi.org/10.1016/j.ard.2026.06.009},
  note = {CC BY-NC-ND},
}

TY  - JOUR
TI  - 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis
AU  - Chetan B. Mukhtyar
AU  - Elena Nikiphorou
AU  - Alice Bartoletti
AU  - Mrinalini Dey
AU  - Georgina Ducker
AU  - Durga Prasanna Misra
AU  - Sara Monti
AU  - Paul Studenic
AU  - Alvise Berti
AU  - Daniël Blockmans
AU  - Elisabeth Brouwer
AU  - Frank Buttgereit
AU  - Kathleen Cannings
AU  - Maria Cinta Cid
AU  - Richard P. Conway
AU  - Lisa Christ
AU  - Christian Dejaco
AU  - Kresten Krarup Keller
AU  - Lisa Christ
AU  - Peter A. Merkel
AU  - Aladdin J Mohammad
AU  - Susan P. Mollan
AU  - Berit Dalsgaard Nielsen
AU  - Cristina Ponte
AU  - David Saadoun
AU  - Wolfgang Schmidt
AU  - Kenneth J. Warrington
AU  - Bernhard Hellmich
PY  - 2026
DA  - 2026/07/01
JO  - Annals of the Rheumatic Diseases
DO  - 10.1016/j.ard.2026.06.009
UR  - https://doi.org/10.1016/j.ard.2026.06.009
AB  - OBJECTIVES: This study aimed to update the European Alliance of Associations for Rheumatology (EULAR) recommendations for management of polymyalgia rheumatica (PMR), giant cell arteritis (GCA), and Takayasu arteritis (TAK). METHODS: Following EULAR standard operating procedures, systematic literature reviews identified data published since the previous versions for PMR (2015) and for GCA/TAK (2018). An international task force discussed the evidence, and following a structured voting process, created overarching principles, recommendations, and quality indicators. RESULTS: The task force agreed on 4 overarching principles, 12 recommendations, and 2 quality indicators. All patients with suspected PMR, GCA, or TAK should be referred for specialist assessment and those with suspected GCA within 24 hours. In patients with a strong clinical suspicion of GCA, treatment with glucocorticoids (GCs) should be commenced without delay, while waiting for the results of confirmatory investigations. For most patients with suspected PMR or TAK, treatment with GC can be delayed until the diagnosis is confirmed. For induction of remission, GC should be initiated at a dose of 15 to 25 mg/day prednisone-equivalent for PMR and 40 to 60 mg for GCA or TAK. Guidance on GC tapering is provided. Adjunctive therapy is recommended for selected patients with PMR or GCA using either interleukin (IL)-6 receptor inhibitors for PMR and GCA or upadacitinib for GCA. Methotrexate may be an alternative. GC-sparing agents should be given in combination with GC to all patients with TAK. All overarching principles and recommendations met with high levels of agreement. CONCLUSIONS: Updated guidance on management of PMR and large vessel vasculitis is provided in a single set of practical recommendations and algorithms.
SN  - 0003-4967
SN  - 1468-2060
ER  -